Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 12/20 | 0.54 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4127878 | 1.00 | MTNR1B (0.54) | MTNR1BMTNR1AKDM4EALDH1A1LMNA | |
| SCHEMBL4136755 | 0.92 | MTNR1B (0.61) | MTNR1BMTNR1A | |
| SCHEMBL4136757 | 0.92 | MTNR1B (0.61) | MTNR1BMTNR1A | |
| SCHEMBL9748795 | 0.85 | DRD1 (0.48) | MTNR1BMTNR1AKDM4EALDH1A1LMNA | |
| SCHEMBL9748779 | 0.85 | DRD1 (0.48) | MTNR1BMTNR1AKDM4EALDH1A1LMNA | |
| SCHEMBL9748787 | 0.85 | DRD1 (0.48) | MTNR1BMTNR1AKDM4EALDH1A1LMNA | |
| SCHEMBL4128332 | 0.79 | SLC18A3 (0.41) | MTNR1BMTNR1AKDM4EALDH1A1 | |
| SCHEMBL4128329 | 0.79 | SLC18A3 (0.41) | MTNR1BMTNR1AKDM4EALDH1A1 | |
| SCHEMBL4128336 | 0.79 | SLC18A3 (0.41) | MTNR1BMTNR1AKDM4EALDH1A1 | |
| SCHEMBL4127552 | 0.76 | FAAH (0.44) | MTNR1BMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612061-B2 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2009-11-03 | — | — | US | disclosed |
| US-20090076030-A1 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2009-03-19 | — | — | US | disclosed |
| US-20090075982-A1 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2009-03-19 | — | — | US | disclosed |
| US-7465733-B2 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2008-12-16 | — | — | US | disclosed |
| EP-1710240-B1 | Piperazine derivatives and their use as serotonin reuptake inhibitors or as neurokinin antagonists | SERVIER LAB (FR) | 2007-12-05 | — | — | EP | disclosed |
| US-20060229318-A1 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-12 | — | — | US | disclosed |
| EP-1710240-A1 | Piperazine derivatives and their use as serotonin reuptake inhibitors or as neurokinin antagonists | Les Laboratoires Servier (FR) | 2006-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075982-A1 | Piperazine compounds | HTR7, HTR5A, NPY5R | MTNR1B 187/4885MTNR1A 156/4885KDM4E 1843/4885 |
| US-20090076030-A1 | Piperazine compounds | HTR7, HTR5A, NPY5R | MTNR1B 187/4885MTNR1A 156/4885KDM4E 1843/4885 |
| US-20060229318-A1 | Piperazine compounds | HTR7, HTR5A, NPY5R | MTNR1B 187/4885MTNR1A 156/4885KDM4E 1843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.